Investors may wish to note that the Independent Chairman of the Board of Castle Biosciences, Inc., Daniel Bradbury, recently netted US$79k from selling stock, receiving an average price of US$62.94. On the bright side, that's just a small sale and only reduced their holding by 0.4%.
Castle Biosciences Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the Chief Business Officer, Bernhard Spiess, sold US$2.0m worth of shares at a price of US$49.97 per share. That means that even when the share price was below the current price of US$61.30, an insider wanted to cash in some shares. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was 77% of Bernhard Spiess's holding.
In the last year Castle Biosciences insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 5.3% of Castle Biosciences shares, worth about US$82m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Castle Biosciences Tell Us?
An insider sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Castle Biosciences. While conducting our analysis, we found that Castle Biosciences has 3 warning signs and it would be unwise to ignore these.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryCSTL
Latest Nasdaq-Listed Companies Videos
- Altimeter is on track to Grab its target
- Some Activision Blizzard, Inc. (NASDAQ:ATVI) Shareholders Look For Exit As Shares Take 25% Pounding
- Pulling back 14% this week, MercadoLibre's NASDAQ:MELI) five-year decline in earnings may be coming into investors focus
- As Clover Health Investments, Corp.'s market cap (NASDAQ:CLOV) drops to US$2.0b, insiders might be questioning their decision to buy earlier this year